Timothy E. Ritter

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Brian G. Feagan, Silvio Danese, Edward V. Loftus et al. · The Lancet · 2021 · 415 citations

Inflammation, Chronic Inflammatory Diseases, Functional Gastrointestinal Disorder +5

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

Miguel Regueiro, Brian G. Feagan, Bin Zou et al. · Gastroenterology · 2016 · 320 citations · Full text

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

William J. Sandborn, Séverine Vermeire, Laurent Peyrin‐Biroulet et al. · The Lancet · 2023 · 304 citations · Full text

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 277 citations

Immunology, Clinical Trials, Gastroenterology +7

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan, Bruce E. Sands, William J. Sandborn et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 208 citations

Systemic Treatment, Golimumab Monotherapy, Gastroenterology +4